Tower Research Capital LLC TRC grew its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 3,620.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,315 shares of the biopharmaceutical company’s stock after acquiring an additional 11,984 shares during the period. Tower Research Capital LLC TRC’s holdings in Alexion Pharmaceuticals were worth $1,529,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Advisory Services Network LLC raised its position in Alexion Pharmaceuticals by 145.3% in the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 523 shares during the period. Point72 Asia Hong Kong Ltd raised its position in shares of Alexion Pharmaceuticals by 3,156.7% during the 1st quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 947 shares during the period. Berson & Corrado Investment Advisors LLC bought a new stake in shares of Alexion Pharmaceuticals during the 2nd quarter valued at $205,000. Lucia Wealth Services LLC bought a new stake in shares of Alexion Pharmaceuticals during the 1st quarter valued at $191,000. Finally, Financial Gravity Wealth Inc. bought a new stake in shares of Alexion Pharmaceuticals during the 1st quarter valued at $211,000. Institutional investors and hedge funds own 93.11% of the company’s stock.

In related news, CFO Paul J. Clancy sold 5,241 shares of Alexion Pharmaceuticals stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $131.11, for a total transaction of $687,147.51. Following the completion of the sale, the chief financial officer now owns 93,309 shares in the company, valued at approximately $12,233,742.99. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 4.35% of the company’s stock.

Several analysts have recently commented on ALXN shares. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 13th. Stifel Nicolaus downgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price objective for the company from $154.00 to $130.00 in a research report on Tuesday, August 7th. JPMorgan Chase & Co. raised their price objective on shares of Alexion Pharmaceuticals from $184.00 to $188.00 and gave the company an “overweight” rating in a research report on Friday, July 27th. ValuEngine cut shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 8th. Finally, Credit Suisse Group raised their target price on shares of Alexion Pharmaceuticals from $149.00 to $154.00 and gave the company an “outperform” rating in a research note on Tuesday, June 5th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and sixteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $157.56.

ALXN opened at $118.20 on Friday. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $102.10 and a fifty-two week high of $147.29. The firm has a market cap of $26.34 billion, a P/E ratio of 22.91, a P/E/G ratio of 1.14 and a beta of 0.84. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.72 and a quick ratio of 2.27.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.58. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $976.81 million. During the same period last year, the company posted $1.56 EPS. The business’s revenue was up 14.5% on a year-over-year basis. research analysts predict that Alexion Pharmaceuticals, Inc. will post 6.45 EPS for the current year.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Article: Find a Trading Strategy That Works

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.